Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro.

AD Cambrey, NK Harrison, KE Dawes… - American journal of …, 1994 - atsjournals.org
AD Cambrey, NK Harrison, KE Dawes, AM Southcott, CM Black, RM du Bois, GJ Laurent…
American journal of respiratory cell and molecular biology, 1994atsjournals.org
Pulmonary fibrosis is a major cause of morbidity and mortality in patients with systemic
sclerosis (SSc). The pathogenesis of this condition is poorly understood, but one of the
earliest pathologic features is endothelial and epithelial cell injury with subsequent
regeneration. Endothelial and epithelial cells can release several mediators, including
endothelin-1 (ET-1). In this study, we investigated the levels of ET-1 in bronchoalveolar
lavage fluid (BALF) from patients with SSc and assessed the contribution of ET-1 to the …
Pulmonary fibrosis is a major cause of morbidity and mortality in patients with systemic sclerosis (SSc). The pathogenesis of this condition is poorly understood, but one of the earliest pathologic features is endothelial and epithelial cell injury with subsequent regeneration. Endothelial and epithelial cells can release several mediators, including endothelin-1 (ET-1). In this study, we investigated the levels of ET-1 in bronchoalveolar lavage fluid (BALF) from patients with SSc and assessed the contribution of ET-1 to the fibroblast mitogenic activity induced by these fluids. A total of 26 patients were evaluated and divided into those with evidence of pulmonary fibrosis, assessed by thin-section computed tomography (group I, n = 16), and those with a normal scan (group II, n = 10). BALF from both groups of patients stimulated fibroblast proliferation. Values expressed as median (range) percentage increase above media controls were 25.5% (5.0 to 47.8%) and 27.6% (10.9 to 51.6%) for groups I and II, respectively (P < 0.02 in both cases). Mitogenic activity was inhibited by about 40% in the presence of either a neutralizing antibody to ET-1 or two synthetic ET-1 receptor ligands. Levels of ET-1 in BALF, expressed as medians (range) were 2.90 ng/mg albumin (0.68 to 5.75) in patients with SSc and 1.23 ng/mg albumin (0.84 to 2.0) in control patients (P < 0.02). Furthermore, ET-1 levels in BALF from patients in group II (3.83 ng/mg albumin, range 1.76 to 5.75) were elevated compared with those in group I (2.62 ng/mg albumin, range 0.68 to 3.81; P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
ATS Journals